Atsuko Umezawa

Sagamihara, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

CD109 Expression in Tumor and Stromal Cells Serves as a Prognostic Biomarker for Tumor Progression and Outcome in Gallbladder Adenocarcinoma.

CD109 Expression in Tumor and Stromal Cells Serves as a Prognostic Biomarker for Tumor Progression and Outcome in Gallbladder Adenocarcinoma.

Journal: Pathology international

Published: October 25, 2025

REV7 Expression Is Associated with Tumor Cell Growth and Cisplatin Resistance in Gallbladder Adenocarcinoma.

REV7 Expression Is Associated with Tumor Cell Growth and Cisplatin Resistance in Gallbladder Adenocarcinoma.

Journal: Pathobiology : journal of immunopathology, molecular and cellular biology

Published: June 22, 2025

REV7 subunit of mutagenic DNA polymerase ζ as a predictive biomarker for the efficacy of immune checkpoint inhibitor therapy in melanoma.

REV7 subunit of mutagenic DNA polymerase ζ as a predictive biomarker for the efficacy of immune checkpoint inhibitor therapy in melanoma.

Journal: Journal of clinical pathology

Published: April 10, 2025

High levels of REV7 expression are associated with poor prognosis and chemoresistance in gastric adenocarcinoma.

High levels of REV7 expression are associated with poor prognosis and chemoresistance in gastric adenocarcinoma.

Journal: Pathology international

Published: September 07, 2024

REV7 is involved in outcomes of platinum-based chemotherapy in pancreatic cancer by controlling the DNA damage response.

REV7 is involved in outcomes of platinum-based chemotherapy in pancreatic cancer by controlling the DNA damage response.

Journal: Cancer science

Published: September 05, 2023

Upregulation of REV7 correlates with progression of malignant melanoma.

Upregulation of REV7 correlates with progression of malignant melanoma.

Journal: Pathology international

Published: June 25, 2021

Increased expression of REV7 in small cell lung carcinomas and its association with tumor cell survival and proliferation.

Increased expression of REV7 in small cell lung carcinomas and its association with tumor cell survival and proliferation.

Journal: Pathology international

Published: September 14, 2020

Inactivation of REV7 enhances chemosensitivity and overcomes acquired chemoresistance in testicular germ cell tumors.

Inactivation of REV7 enhances chemosensitivity and overcomes acquired chemoresistance in testicular germ cell tumors.

Journal: Cancer letters

Published: March 19, 2020

CD109, a negative regulator of TGF-β signaling, is a putative risk marker in diffuse large B-cell lymphoma.

CD109, a negative regulator of TGF-β signaling, is a putative risk marker in diffuse large B-cell lymphoma.

Journal: International journal of hematology

Published: October 04, 2016

High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.

High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.

Journal: International journal of hematology

Published: August 25, 2015

Showing 1-10 of 10

Last Updated: 09/26/2026